Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PCMTD1 divergent transcript (PCMTD1-DT, LOC124901944) is a long noncoding RNA (lncRNA) transcribed from the promoter region of the PCMTD1 gene and in the opposite orientation, a phenomenon referred to as divergent transcription.[3] Divergent transcripts are commonly found near promoters of protein-coding genes and can play roles in chromatin structure, transcriptional regulation, and origination of new genes over evolutionary timescales. Currently, there is no evidence that PCMTD1-DT encodes a protein, functions as a therapeutic target, or serves as a biomarker. The functional significance of most divergent noncoding transcripts—including PCMTD1-DT—remains unclear in mammalian genomes, and specific biological functions or disease associations have not been established[3]. The nearby protein-coding gene, PCMTD1, has been genetically linked to primary angle-closure glaucoma, but such disease roles are not assigned directly to PCMTD1-DT[1][2]. If you require information about the protein-coding gene PCMTD1, let me know. For the specified transcript, available data support its status as a noncoding RNA, not a classical therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PCMTD1 divergent transcript (PCMTD1-DT).